Previous 10 | Next 10 |
2023-07-17 01:57:28 ET Exicure press release ( NASDAQ: XCUR ): Q1 GAAP EPS of -$0.70. Cash, cash equivalents and restricted cash were $11.2 million as of March 31, 2023, as compared to $9.8 million as of December 31, 2022. The company expects that its cash and cash equ...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...
2023-07-14 08:34:41 ET EdtechX Holdings ( NASDAQ: EDTX ) +68% . ARB IOT Group ( ARBB ) +48% . PainReform ( PRFX ) +35% . Nutriband ( NTRB ) +35% . Western Acquisition Ventures ( WAVS ) +20% . Nik...
2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% . Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...
2023-05-26 16:18:18 ET Exicure ( NASDAQ: XCUR ) said Friday that the company's board supports CEO Jung Sang Kim's view to continue exploring strategic alternatives for the company. "These efforts include the possible sale of certain of the company’s...
Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic...
2023-05-19 16:23:49 ET Exicure ( NASDAQ: XCUR ) said Friday it received a notice of non-compliance from Nasdaq for not filing its form 10-Q for the quarterly period ended March 31, 2023 on time. The company said is working diligently to complete its form 10-Q and intends to fi...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely fil...
2023-05-04 16:58:14 ET Exicure ( NASDAQ: XCUR ) has invested in Cyworld Z, the operator of the Korean SNS platform "Cyworld," the company said on Thursday. The company has purchased $1 million convertible bonds issued by Cyworld Z as part of the investment. The company sai...
News, Short Squeeze, Breakout and More Instantly...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely f...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...